liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Impact of Interleukin-28B gene polymorphism [rs12979860] on Egyptian patients infected with hepatitis C virus genotype-4
Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Show others and affiliations
2013 (English)In: Eastern Mediterranean Health Journal, ISSN 1020-3397, E-ISSN 1687-1634, Vol. 19, no Supp. 3, p. 98-104Article in journal (Refereed) Published
Abstract [en]

Single nucleotide polymorphisms (SNPs) in the Interleukin (IL)-28B gene, namely rs12979860, could predict response to pegylated interferon-α-ribavirin (PR) therapy in hepatitis C virus genotype 1 (HCV-1)-infected patients. A similar role was investigated in a case-control study conducted on 93 Egyptian patients chronically infected with HCV-4 in comparison to 22 individuals with spontaneous HCV clearance and 70 healthy volunteers. The homozygous C allele genotype (CC) was associated with sustained viral response (SVR) to therapy compared with the homozygous T allele genotype (TT) and the heterozygous genotype (CT). In the SVR group, the response rate was statistically significantly higher in CC genotypes (58.6%) compared with CT/TT (20.3%). There was no correlation between SVR patients' genotypes and early response to therapy or HCV baseline viral load. Our findings describe how IL-28B SNP genotyping may guide appropriate selection of HCV-4-infected patients for PR therapy.

Place, publisher, year, edition, pages
Alexandria, Egypt: World Health Organization Regional Office for the Eastern Mediterranean (WHO/EMRO) , 2013. Vol. 19, no Supp. 3, p. 98-104
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:liu:diva-184597DOI: 10.26719/2013.19.supp3.s98OAI: oai:DiVA.org:liu-184597DiVA, id: diva2:1654182
Available from: 2022-04-26 Created: 2022-04-26 Last updated: 2022-05-03Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records

El-Serafi, Ahmed Taher

Search in DiVA

By author/editor
El-Serafi, Ahmed Taher
In the same journal
Eastern Mediterranean Health Journal
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 7 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf